Cover: The Costs of Treating AIDS under Medicaid

The Costs of Treating AIDS under Medicaid


Published 1987

by Anthony H. Pascal


Download eBook for Free

FormatFile SizeNotes
PDF file 2.5 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.


Purchase Print Copy

 Format Price
Add to Cart Paperback63 pages $23.00

AIDS (Acquired Immune Deficiency Syndrome) ranks near the top of the list of major impairments in terms of average lifetime medical costs. A large share of the rapidly escalating costs for treating victims of the AIDS epidemic will fall on the Medicaid program. This Note reports the results of a five-month exploratory research effort that attempted to estimate these costs. The findings are only best estimates, given current knowledge. Combining assumptions as to case load, Medicaid eligibility, average treatment costs, and Medicaid reimbursement rates yields a range of estimate for cumulative Medicaid costs in 1986-1991. The intermediate estimate amounts to about $10 billion, although the most optimistic set of assumptions would yield an estimate as low as $2 billion, and the most pessimistic would produce an estimate as high as $47 billion. National total treatment costs are also estimated.

This report is part of the RAND note series. The note was a product of RAND from 1979 to 1993 that reported other outputs of sponsored research for general distribution.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.